SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...

For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time vs placebo.

For patients with Parkinson's disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist ...

Therapies that use stem cells to repair or replace damaged cells in the brains of patients with Parkinson’s disease have been ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

Oral carbidopa-levodopa formulation improves sleep in Parkinson disease, particularly addressing sleep disturbances and ...

Get Instant Summarized Text (Gist) Levodopa, a dopamine-enhancing medication, may improve motivation in depression linked to high inflammation. Individuals with C-reactive protein (CRP) levels ...

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Further information Decision makers have concluded that the clear rationale to not evaluate this product is due to it being a change to the formulation of an existing product as per section 7.1.3 of ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

However, I doubt that is a very good estimate given the nearly 1 million Americans with PD. Levodopa/Carbidopa remain the most effective treatments, with other modalities being dopamine agonists ...